IDD Stock Overview
A biotechnology company, develops immunotherapies for cancer patients in France and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Innate Pharma S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.03 |
52 Week High | €2.96 |
52 Week Low | €1.99 |
Beta | 0.71 |
11 Month Change | -19.76% |
3 Month Change | -5.36% |
1 Year Change | -30.36% |
33 Year Change | -30.29% |
5 Year Change | -63.78% |
Change since IPO | -56.99% |
Recent News & Updates
Recent updates
Shareholder Returns
IDD | DE Biotechs | DE Market | |
---|---|---|---|
7D | -4.0% | 4.0% | 0.008% |
1Y | -30.4% | -19.3% | 3.1% |
Return vs Industry: IDD underperformed the German Biotechs industry which returned -19.3% over the past year.
Return vs Market: IDD underperformed the German Market which returned 3.1% over the past year.
Price Volatility
IDD volatility | |
---|---|
IDD Average Weekly Movement | 6.6% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: IDD's share price has been volatile over the past 3 months.
Volatility Over Time: IDD's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 179 | Herve Brailly | www.innate-pharma.com |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Innate Pharma S.A. Fundamentals Summary
IDD fundamental statistics | |
---|---|
Market cap | €166.35m |
Earnings (TTM) | -€7.57m |
Revenue (TTM) | €61.64m |
2.7x
P/S Ratio-22.0x
P/E RatioIs IDD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IDD income statement (TTM) | |
---|---|
Revenue | €61.64m |
Cost of Revenue | €56.02m |
Gross Profit | €5.62m |
Other Expenses | €13.19m |
Earnings | -€7.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 12, 2024
Earnings per share (EPS) | -0.094 |
Gross Margin | 9.12% |
Net Profit Margin | -12.28% |
Debt/Equity Ratio | 75.3% |
How did IDD perform over the long term?
See historical performance and comparison